Khurana RN, Merrill P, Yeh S, et al. - In this multicentre, non-interventional extension study (MAGNOLIA), researchers sought to evaluate the extended effectiveness and safety of suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) among patients with macular oedema secondary to non-infectious uveitis. Thirty-three patients were enrolled (28 CLS-TA and 5 control) out of the 53 eligible patients (46 CLS-TA and 7 control). There were no serious adverse events associated with the study treatment. According to findings, nearly half of the patients did not require any additional treatment for up to 9 months after their last CLS-TA administration.